Recent FDA approval of the Smo inhibitors, vismodegib, and sonidegib for the treatment of advanced basal cell carcinoma (BCC) and entry of other Smo inhibitors into clinical trials for pediatric medulloblastoma raise the possibility of expanding these inhibitors into clinical trials for pediatric RMS (127). This evidence concerns the gene SMO and skin basal cell carcinoma.